Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 19/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11939273 | 0.79 | AR (0.42) | ARCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL25197764 | 0.78 | AR (0.41) | ARCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL324996 | 0.78 | AR (0.57) | AR | |
| SCHEMBL11692127 | 0.74 | AR (0.42) | AR | |
| SCHEMBL2430432 | 0.74 | AR (0.39) | ARCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL12327569 | 0.74 | AR (0.39) | ARCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2968418 | 0.74 | AR (0.42) | ARPGR | |
| SCHEMBL582563 | 0.73 | CYP1A2 (0.47) | ARCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL10070054 | 0.71 | AR (0.37) | ARCYP3A4PGR | |
| SCHEMBL10069507 | 0.71 | AR (0.37) | ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208985-A2 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208985-A2 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-06-27 | — | — | US | disclosed |
| US-20230133119-A1 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230133119-A1 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-05-04 | — | — | US | disclosed |
| EP-4121044-A1 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021189051-A1 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021189051-A1 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2021-09-23 | — | — | WO | disclosed |
| US-9920044-B2 | Selective androgen receptor modulators | RADIUS PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920044-B2 | Selective androgen receptor modulators | RADIUS PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920044-B2 | Selective androgen receptor modulators | RADIUS PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-7470797-B2 | Fused heterocyclic imido and amido compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470797-B2 | Fused heterocyclic imido and amido compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-7405234-B2 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405234-B2 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| US-20080139631-A1 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139631-A1 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080108649-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108649-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| WO-2008042571-A2 | SUBSTITUTED INDOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008042571-A2 | SUBSTITUTED INDOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208985-A2 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | AR, SHBG, NR5A1 | AR 1/4885CYP1A2 1586/4885CYP3A4 2576/4885 |
| US-20080108649-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | AR, ESRRA, SHBG | AR 1/4885CYP1A2 249/4885CYP3A4 516/4885 |
| US-20230133119-A1 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | AR, SHBG, NR5A1 | AR 1/4885CYP1A2 1594/4885CYP3A4 2516/4885 |
| US-20080139631-A1 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | AR, NR5A1, NR3C2 | AR 1/4885CYP1A2 2148/4885CYP3A4 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.